Zacks Investment Research on MSN
Down 24% in 4 weeks, here's why Nuvation Bio (NUVB) looks ripe for a turnaround
Nuvation Bio Inc. (NUVB) has been beaten down lately with too much selling pressure. While the stock has lost 24.1% over the ...
CoreWeave shares are down on Tuesday, pulling back following Monday's strength, as the company's CEO, Michael Intrator, ...
Affirm shares are down on Tuesday as investors react to President Donald Trump's ultimatum regarding credit card interest ...
Spanish police have announced what it says is the biggest-ever European drugs bust from a cargo vessel. A small ship named as ...
Quick Summary ChatGPT thinks Okta stock could climb to $121.94 by late March, projecting upside from current levels as improving margins and steady demand for identity security support a continued ...
Monero breaks into all-time-high territory while Dash records its largest move since October. Privacy coins are heating ...
Ethereum extends gains on ETF inflows and the BPO blob upgrade, boosting scalability, while an overbought RSI signals ...
PayPal’s stock price has remained under pressure this year and has moved to its lowest level since April last year. It ...
Activity across major crypto networks is starting to move in different directions as traders focus more on execution, ...
Zacks Investment Research on MSN
Down 37% in 4 weeks, here's why Aquestive Therapeutics (AQST) looks ripe for a turnaround
A downtrend has been apparent in Aquestive Therapeutics (AQST) lately with too much selling pressure. The stock has declined 37% over the past four weeks. However, given the fact that it is now in ...
BNB price recovery is poised for a major breakout from $923 as Binance's exchange metric continues to project strong growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results